Dana Rabara

Statistics

Publications

Citations

329

H-Index

Active since

2019

Affiliations

Frederick National Laboratory for Cancer Research(Current)

UCSF Helen Diller Family Comprehensive Cancer Center

University of California, San Francisco

Leidos (United States)

Leidos Biomedical Research Inc. (United States)

Dana Rabara is an author at Frederick National Laboratory for Cancer Research specializing in ras family oncogenes, cell signaling, and molecular biology.

ORCID

Publications per year

2019–2025

Publications

KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis

Dana Rabara, Timothy H. Tran, Srisathiyanarayanan Dharmaiah et al. · Proceedings of the National Academy of Sciences · 2019 · 129 citations · Full text

Medicine, Molecular Biology, Oncology +17

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

Anna E. Maciag, James P. Stice, Bin Wang et al. · Cancer Discovery · 2024 · 45 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer

Mukul Sherekar, Sae‐Won Han, Rodolfo Ghirlando et al. · Journal of Biological Chemistry · 2019 · 44 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer

Mukul Sherekar, Sae‐Won Han, Rodolfo Ghirlando et al. · Journal of Biological Chemistry · 2020 · 38 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

Dhirendra K. Simanshu, Rui Xu, James P. Stice et al. · Science · 2025 · 28 citations

Medicine, Oncology, Pharmacology +17

1–5 of 8